What is STRIBILD?

STRIBILD is a prescription medicine used as a complete single tablet regimen to treat HIV-1 in adults. STRIBILD should not be used with other HIV-1 medicines. With STRIBILD, you have everything you need to treat HIV-1 in just 1 pill, taken once a day with food.

STRIBILD combines 4 medicines in 1 pill

STRIBILD combines the medicines in TRUVADA (emtricitabine and tenofovir disoproxil fumarate) + TYBOST (cobicistat) + VITEKTA (elvitegravir) for a
complete 1-pill, once-a-day HIV-1 treatment.

STRIBILD is for:

  • People who have never taken HIV-1 medicines before
  • Some people who are considering replacing their current HIV-1 medicines and have an undetectable viral load (less than 50 copies/mL of virus in their blood) and their healthcare provider determines that they meet certain other requirements
  • People who are 18 years old or older (it is not known if STRIBILD is safe and effective in people younger than 18 years)

Talk to your healthcare provider to see if STRIBILD is the right treatment choice for you. STRIBILD does not cure HIV-1 infection or AIDS.

To control HIV-1 infection and decrease HIV-related illnesses you must keep taking STRIBILD. Ask your healthcare provider if you have questions about how to reduce the risk of passing HIV-1 to others. Always practice safer sex and use condoms to lower the chance of sexual contact with body fluids. Never reuse or share needles or other items that have body fluids on them.

How do we know STRIBILD works?

STRIBILD was studied in four separate trials designed to measure the side effects of the medicines and to see how many patients either achieved OR maintained undetectable viral loads.

In these studies, "undetectable" meant that patients had less than 50 copies of HIV-1 per milliliter (mL) of blood at the end of the studies.

  • Each trial compared STRIBILD against medicines proven to treat HIV-1.
  • The trials included both men and women; however, most of the patients in these studies were men.
  • Each patient was randomly given either STRIBILD or another proven HIV-1 medicine.

Studies of patients new to HIV-1 therapy who started treatment with STRIBILD

  • All patients in Studies 103 and 102 trials were adults who had never taken an HIV-1 medicine before and had normal kidney function.*
  • For Studies 103 and 102, at the end of three years, doctors were told which medicine the patients had been taking, and they measured the results.

*In Study 103, the other medicines were atazanavir, ritonavir, and the combination of emtricitabine and tenofovir disoproxil fumarate. In Study 102, the other medicines were a combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

Click here to see the results of these studies >

Studies of patients replacing their current treatment with STRIBILD

  • Patients in Studies 115 and 121 were adults who:
    • Were taking their first or second HIV-1 medicine
    • Had normal kidney function
    • Had an undetectable viral load on their current HIV medicines for at least 6 months
    • Had never failed a past HIV treatment
  • Patients were randomly assigned to stay on their current medicine or replace it with STRIBILD*
  • Studies 115 and 121 were open-label studies, which simply means that everyone knew which medicines they were taking during the trials.

*In Study 115, the current HIV-1 medicines were a protease inhibitor, ritonavir, and the combination of emtricitabine and tenofovir disoproxil fumarate. In Study 121, the current HIV-1 medicines were a non-nucleoside reverse transcriptase inhibitor and the combination of emtricitabine and tenofovir disoproxil fumarate.

Click here to see the results of these studies >



IMPORTANT SAFETY INFORMATION

What is the most important information I should know about STRIBILD?

STRIBILD can cause serious side effects:

  • Build-up of an acid in your blood (lactic acidosis), which is a serious medical emergency. Symptoms of lactic acidosis include feeling very weak or tired, unusual (not normal) muscle pain, trouble breathing, stomach pain with nausea or vomiting, feeling cold especially in your arms and legs, feeling dizzy or lightheaded, and/or a fast or irregular heartbeat
  • Serious liver problems. The liver may become large (hepatomegaly) and fatty (steatosis). Symptoms of liver problems include your skin or the white part of your eyes turns yellow (jaundice), dark “tea-colored” urine, light-colored bowel movements (stools), loss of appetite for several days or longer, nausea, and/or stomach pain
  • You may be more likely to get lactic acidosis or serious liver problems if you are female, very overweight (obese), or have been taking STRIBILD for a long time. In some cases, these serious conditions have led to death. Call your healthcare provider right away if you have any symptoms of these conditions
  • Worsening of hepatitis B (HBV) infection. If you also have HBV and stop taking STRIBILD, your hepatitis may suddenly get worse. Do not stop taking STRIBILD without first talking to your healthcare provider, as they will need to monitor your health. STRIBILD is not approved for the treatment of HBV

What is STRIBILD?

STRIBILD® is a prescription medicine used to treat HIV-1 in adults who have never taken HIV-1 medicines before. STRIBILD can also replace current HIV-1 medicines for some adults who have an undetectable viral load (less than 50 copies/mL of virus in their blood) and whose healthcare provider determines that they meet certain other requirements. STRIBILD combines 4 medicines into 1 pill to be taken once a day with food. STRIBILD is a complete single tablet regimen and should not be used with other HIV-1 medicines.

STRIBILD does not cure HIV-1 infection or AIDS. To control HIV-1 infection and decrease HIV-related illnesses you must keep taking STRIBILD. Ask your healthcare provider if you have questions about how to reduce the risk of passing HIV-1 to others. Always practice safer sex and use condoms to lower the chance of sexual contact with body fluids. Never reuse or share needles or other items that have body fluids on them.

The information in this section is intended for residents of the United States who are 18 years of age or older.

By following this link, you are now leaving
www.STRIBILD.com. This site is not controlled
by Gilead Sciences, Inc. Gilead Sciences, Inc. is not
responsible for the site's content or your use of it.

GET UPDATES

Sign up to receive updates when new information on STRIBILD is made available.


Submit

Terms and conditions

Gilead respects the privacy of your personal information. Gilead, and companies providing services to Gilead, may use the information that you provide to send you marketing or informational materials, analyze and use your information to improve or develop services and programs, and contact you about marketing programs or research and health topics that may be of interest to you.

Gilead, and companies providing services to Gilead, will not sell or rent your personally identifiable information. For more information regarding our Privacy Policy, click here.
Print

Thank you.

You will be notified as new information is made available on this Web site.